Nasdaq · CIK 0001904286
MIRA MIRA PHARMACEUTICALS, INC.
Insider trading from SEC Form 4. Last filing Apr 1, 2026. Close $0.75 on Oct 9, 2026, +22% from the 52-week low and -59% from the high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at MIRA PHARMACEUTICALS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 16Weak | Erez Aminov Chief Executive Officer sell | $134k 100,000 shares | -9% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 19, 2024 | Erez Aminov Affiliate | 100,000 0.60% of outstanding | $141k | Nov 19, 2024 | none |
Transactions
The last 15 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | Erez Aminov Chief Executive Officer | AGrant or award Restricted Stock Unitsderivative | +83,500 | $0.00 | $0 | 83,500 | Apr 1, 2026 |
| Oct 1, 2025 | Erez Aminov Chief Executive Officer | AGrant or award Common Stock | +2,685,456 | - | - | 3,530,156 | Oct 3, 2025 |
| Oct 1, 2025 | Denil Nanji Shekhat director | AGrant or award Common Stock | +22,378 | $1.35 | $30k | 22,378 | Oct 3, 2025 |
| Sep 18, 2025 | Erez Aminov Chief Executive Officer | AGrant or award Stock Options (right to buy)derivative10b5-1 | +150,000 | $0.00 | $0 | 150,000 | Sep 18, 2025 |
| Sep 18, 2025 | Erez Aminov Chief Executive Officer | AGrant or award Stock Options (right to buy)derivative10b5-1 | +150,000 | $0.00 | $0 | 150,000 | Sep 18, 2025 |
| Aug 29, 2025 | Erez Aminov Chief Executive Officer | AGrant or award Common Stock | +62,500 | $1.37 | $86k | 844,700 | Sep 3, 2025 |
| Dec 9, 2024 | Erez Aminov Chief Executive Officer | AGrant or award Stock Options (right to buy)derivative | +2,000,000 | $0.00 | $0 | 2,000,000 | Dec 10, 2024 |
| Dec 9, 2024 | Matthew Paul Del Giudice director | AGrant or award Stock Options (right to buy)derivative | +25,000 | $0.00 | $0 | 75,000 | Dec 10, 2024 |
| Dec 9, 2024 | Edward Clouston MacPherson director | AGrant or award Stock Options (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 10, 2024 |
| Dec 9, 2024 | Denil Nanji Shekhat director | AGrant or award Stock Options (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Dec 10, 2024 |
| Dec 9, 2024 | Matthew Pratt Whalen director | AGrant or award Stock Options (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 10, 2024 |
| Dec 9, 2024 | Michelle Yanez Chief Financial Officer | AGrant or award Stock Options (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 10, 2024 |
| Dec 9, 2024 | Erez Aminov Chief Executive Officer | AGrant or award Restricted Stock Unitsderivative | +500,000 | $0.00 | $0 | 500,000 | Dec 10, 2024 |
| Nov 19, 2024 | Erez Aminov Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -55,410 | $1.39 | $77k | 1,105,790 | Nov 27, 2024 |
| Nov 20, 2024 | Erez Aminov Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -44,590 | $1.27 | $57k | 1,061,200 | Nov 27, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Erez AminovChief Executive Officer
- Matthew Paul Del Giudicedirector
- Edward Clouston MacPhersondirector
- Denil Nanji Shekhatdirector
- Matthew Pratt Whalendirector
- Michelle YanezChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.